Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

(2012) W. Blum et al.   BLOOD

Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients

(2011) U. Brunnberg et al.   ANNALS OF ONCOLOGY

Absence of Class II-Associated Invariant Chain Peptide on Leukemic Blasts of Patients Promotes Activation of Autologous Leukemia-Reactive CD4+ T Cells

(2011) M. M. van Luijn et al.   CANCER RESEARCH

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

(2011) M R Baer et al.   LEUKEMIA

Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

(2010) Jorge E. Romaguera et al.   BRITISH JOURNAL OF HAEMATOLOGY

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

(2009) Alan K. Burnett et al.   BRITISH JOURNAL OF HAEMATOLOGY

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study

(2009) Oliver Weigert et al.   LEUKEMIA & LYMPHOMA

Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with the proteasome status

(2009) Mariette Matondo et al.   LEUKEMIA RESEARCH

Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia

(2008) E. C. Attar et al.   CLINICAL CANCER RESEARCH